Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Anamorelin (Primary)
- Indications Anorexia; Cachexia
- Focus Registrational; Therapeutic Use
- Sponsors Helsinn Healthcare SA
- 24 Oct 2023 Results of two studies NCT03743051 & NCT03743064 comparing anamorelin and weight gain in patients with advanced non-small cell lung cancer (NSCLC) and cachexia were presented at the 48th European Society for Medical Oncology Congress.
- 03 Apr 2023 Status changed from active, no longer recruiting to completed.
- 16 Mar 2023 This trial has been completed in Poland (Global end date: 27 Dec 2022).